Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Latest innovations in RayStation, RayCare and RayIntelligence to be presented at ASTRO 2023

STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- RaySearch will be showcasing the latest software innovations at ASTRO in San Diego, California, October 1-4. Participants can book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and cloud-based oncology analytics system RayIntelligence®, in RaySearchs's booth 3245 during the event.

RayStation 2023B offers support for automatic field-in-field planning for photons, a method which generates homogeneous and conformal dose distributions by combining a few subfields, and point-based optimization of brachytherapy plans, and more efficient data loading. Attendees can experience the next steps in workflow improvements for dose tracking and adaptive replanning. Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be highlighted.

The latest version of RayCare includes enhanced treatment schedules, support for enhanced data migration, including feature and usability updates to the patient chart and task management. Attendees will be able to experience the new dedicated workspace for treatment course management which supports all user needs in relation to managing the fractionation schedule for treatments including assignment of plans, managing treatment settings, and handling approvals.

RaySearch's latest product, the cloud-based oncology analytics system RayIntelligence will also be demonstrated during the congress. RayIntelligence features support such as import of DICOM data and new clinical goals dashboards.

Johan Löf, founder and CEO, RaySearch, says: "We're excited to return to ASTRO in San Diego, meeting valued partners as well as customers and potential customers. We are also eager to showcase our latest product innovations to attendees joining us in our booth."

Demonstrations at ASTRO include

Poster presentations

Comprehensive Beam Modeling, Secondary Dose Computations and Treatment Planning for a 1.5 T MRgRTSystem


K Kierkels and G Hilgers, Radiotherapiegroep, Arnhem/Deventer, the Netherlands

C Fälth and A Angerud, RaySearch Laboratories AB, Stockholm, Sweden

Towards clinical proton minibeam radiation therapy (pMBRT): development of clinical pMBRT syst prototype and pMBRT-specific treatment planning method


Yuting Lin, Weijie Zhang, Dan Johnson, Wangyao Li, Gregory N Gan, Ronald C Chen and Hao Gao, Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA

Yolanda Prezado, Institut Curie Research Center, Orsay, France

Erik Traneus, RaySearch Laboratories AB, Stockholm, Sweden

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
[email protected]

The following files are available for download:


RaySearch Press Release September 29, 2023




SOURCE RaySearch Laboratories

These press releases may also interest you

at 08:20
Regal Components, Inc. has introduced custom core pins, sleeves, ejector pins, blades, and punches fabricated in special shapes and sizes from various materials for critical applications. Regal Special Mold & Die Components are suitable for a...

at 08:15
Thermo Fisher Scientific Inc. , the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an...

at 08:15
AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced that Thomas Finn and John Shiver have joined the company's board of directors. They will serve with...

at 08:15
PayGround, a healthcare fintech payments platform, today announced closing a $19.7M oversubscribed Series A financing led by SixThirty with participation from Rally Ventures, IA Capital Group, FCA Venture Partners and Plug and Play Ventures. The...

at 08:15
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") , a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB ("OncoZenge") (STO:ONCOZ), a clinical-stage...

at 08:10
Loyal, a biotech company pioneering longevity drugs for dogs, announced today that the Food and Drug Administration (FDA) Center for Veterinary Medicine has approved the Reasonable Expectation of Effectiveness section of Loyal's conditional approval...

News published on and distributed by: